Healio

Higher B-cell count linked to toxic effects after CAR T-cell therapy in autoimmune disease

Patients who develop cytokine release syndrome after chimeric antigen receptor T-cell therapy for autoimmune disease ...
BIOENGINEER

Hong Kong Team Makes CAR-T Therapy for Children With Leukaemia in Just 14 Days

A Hong Kong phase II trial of six children found that locally manufactured point-of-care CD19 CAR-T cells, produced in 14 ...

Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial

Results from a Phase I clinical trial led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer ...
Medscape

Baseline Blood Markers Linked to Risk for Cytokine Release Syndrome After CAR T-Cell Therapy in Autoimmune Disease

Higher baseline B-cell counts and IL-6 concentrations are associated with an increased risk for cytokine release syndrome ...

Biomarkers identified for cytokine release syndrome risk after CAR T-cell therapy

For patients with autoimmune disease, higher baseline B-cell counts and systemic inflammation are associated with development ...
Healio

‘Complete eradication’ of B cells drives remission after autoimmune CAR T-cell therapy

Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...
BIOENGINEER

B-Cell Depletion Therapy Reshapes Antiviral Immunity in Multiple Sclerosis, Study Finds

A cross-sectional study shows that ocrelizumab selectively contracts EBV-specific CD4 T-cell immunity in multiple sclerosis ...
News-Medical.Net

Enhanced CAR T-cell therapy may improve treatment options for patients with B-cell blood cancers

Results from a phase I clinical trial led by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer ...
Yahoo Finance

Immusoft Announces Presentation of World's First Patient Treated with an Engineered B Cell Therapy at Workshop Co-Hosted by FDA and ARM

SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE)-- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that it will present an invited clinical ...
Cure Today

Off-The-Shelf CAR T Therapy Elicits Responses in Large B-Cell Lymphoma

Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma. Treatment with cemacabtagene ansegedleucel (cema-cel) ...